The findings of the existing trial showed that CFA injections increased the serum levels of MMP-1 and cathepsin K, with a significant concomitant reduction in osteocalcin; these findings concur with other reports of high expressions of MMP-1 and cathepsin K in arthritis [51]. Here, BGLAP is linked to arthritic joint disease.